| 0 | 💬 0 |
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.
(nature.com)
|
Nature Medicine 2026-05-31 | #cancer #clinical trial #immunotherapy #toxicity #tcr |